Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PNU 166196

Known as: PNU-166196, PNU166196 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

brostallicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity… Expand
Is this relevant?
2007
2007
PNU-166196 induces DNA damage measured by histone H2AX phosphorylation independently of the nucleotide excision repair pathways.
B77 PNU-166196 is a DNA minor groove binder in Phase II clinical development. Data suggest that PNU-166196 is activated by… Expand
Is this relevant?
2004
2004
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
The mechanism of action of many antitumor agents involves DNA damage, either by direct binding of the drug to DNA or to DNA… Expand
Is this relevant?
2003
2003
Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells
Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2003
2003
Phase I and Pharmacokinetic Study of Brostallicin ( PNU-166196 ) , a New DNA Minor-Groove Binder , Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer 1
Purpose: Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2003
Review
2003
The discovery of a new potential anticancer drug: a case history.
DNA minor groove binders (MGB) represent a class of anticancer agents whose DNA sequence specificity was hypothesized to lead to… Expand
Is this relevant?
2003
2003
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
PURPOSE Brostallicin (PNU-166196) is a alpha-bromoacrylic DNA minor groove binder, currently in clinical evaluation. This drug… Expand
Is this relevant?
2002
2002
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Brostallicin (PNU-166196) is a synthetic alpha-bromoacrylic, second-generation DNA minor groove binder structurally related to… Expand
  • figure 1
  • table 1
  • table 2
  • table 4
  • figure 2
Is this relevant?
Review
2001
Review
2001
Development of distamycin-related DNA binding anticancer drugs.
The relatively low therapeutic index of the clinically used alkylating agents is probably related to the fact that these… Expand
Is this relevant?
2001
2001
A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.
DNA minor groove binders represent a class of cytotoxic antitumor agents whose DNA sequence specificity may lead to a high… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE